Principal Financial Group Inc Crispr Therapeutics Ag Transaction History

Principal Financial Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$51.17 - $68.18 $1.71 Million - $2.28 Million	-33,418 Reduced 82.57%	7,052 $380,000
Q1 2024 Apr 29, 2024	BUY	$60.67 - $89.12 $2.46 Million - $3.61 Million	40,470 New	40,470 $2.76 Million
Q3 2022 Nov 09, 2022	BUY	$61.1 - $83.78 $16,191 - $22,201	265 Added 3.01%	9,059 $592,000
Q2 2022 Aug 10, 2022	SELL	$43.23 - $73.83 $907 - $1,550	-21 Reduced 0.24%	8,794 $534,000
Q1 2022 May 09, 2022	SELL	$53.19 - $79.24 $18,297 - $27,258	-344 Reduced 3.76%	8,815 $553,000
Q4 2021 Feb 09, 2022	SELL	$70.09 - $111.29 $423,553 - $672,525	-6,043 Reduced 39.75%	9,159 $694,000
Q3 2021 Nov 09, 2021	SELL	$110.2 - $156.64 $267,455 - $380,165	-2,427 Reduced 13.77%	15,202 $1.7 Million
Q2 2021 Aug 10, 2021	BUY	$100.84 - $161.89 $189,075 - $303,543	1,875 Added 11.9%	17,629 $2.85 Million
Q1 2021 May 10, 2021	BUY	$110.72 - $210.04 $1.74 Million - $3.31 Million	15,754 New	15,754 $1.92 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.